A North American healthcare company developing a proprietary, non-invasive platform utilizing small non-coding RNA analysis from urinary exosomes. This innovative technology is designed for early disease detection and monitoring. The platform is powered by a liquid biopsy urine test, offering a novel approach to precision medicine and diagnostics.
The company sought a partner to provide in-depth insights into the European market and support the development of a Go-To-Market strategy. They needed guidance on market dynamics, regulatory considerations, and potential adoption barriers to successfully introduce their new test and establish a strong market presence in Europe.
Novoptim conducted interviews with general practitioners, physicians, patient associations, and representatives from insurance and healthcare systems across France, Germany, Italy, and Spain. Additionally, Novoptim engaged with key opinion leaders (KOLs) throughout Europe to gather insights and assess market needs for the client’s strategic development and positioning.
Novoptim prepared the market landscape report presenting epidemiology, patient journey, healthcare system, insurance and path to reimbursement. Novoptim also recruited 12 top European KOLs for the Advisory Board. Novoptim designed the European clinical validation strategy and developed the European marketing plan.
Whether you’re entering the market or scaling your presence, we’re here to turn your innovation into commercial success.
